Year None20212020201920182017 Oct 20, 2021 F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics PDF Version Sep 16, 2021 F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021 PDF Version Sep 09, 2021 F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference PDF Version Aug 12, 2021 F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update PDF Version Aug 10, 2021 F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285 PDF Version Aug 04, 2021 F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA PDF Version Aug 02, 2021 F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021 PDF Version Jul 26, 2021 F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors PDF Version Jul 09, 2021 F-star Therapeutics to Present at Upcoming Investor Conferences PDF Version Jul 08, 2021 F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors PDF Version Pagination Current page 1 Page 2 Page 3 Next page Next
